Breaking News:

Ebola

Add to Favorites Subscribe Share
Newswise: A Fast and Inexpensive Device to Capture and Identify Viruses
  • Embargo expired:
    23-Dec-2019 12:10 PM EST

A Fast and Inexpensive Device to Capture and Identify Viruses

Penn State Materials Research Institute

A device to quickly capture and identify various strains of virus has been developed, according to researchers at Penn State and New York University.

Channels: Infectious Diseases, Nanotechnology, Ebola, Zika Virus, PNAS, All Journal News,

Released:
20-Dec-2019 12:55 PM EST
Newswise: Research at Argonne's Advanced Photon Source leads to new Ebola drug

Research at Argonne's Advanced Photon Source leads to new Ebola drug

Argonne National Laboratory

Scientists using specialized beamlines at Argonne's Structural Biology Center (SBC), a facility for macromolecular crystallography at the Advanced Photon Source, derived insights that led to the discovery of a promising new drug for Ebola.

Channels: All Journal News, Clinical Trials, DOE Science News, Infectious Diseases, Pharmaceuticals, Vaccines, Ebola, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), DOE Science News,

Released:
9-Dec-2019 2:45 PM EST
Research Results
Newswise: La Jolla Institute for Immunology acquires Berkeley Lights Beacon® platform

La Jolla Institute for Immunology acquires Berkeley Lights Beacon® platform

La Jolla Institute for Immunology

La Jolla Institute for Immunology (LJI) is placing their confidence in Berkeley Lights’ Beacon® Optofluidic Platform and B cell antibody discovery workflow to accelerate the discovery of rare and lifesaving antibodies for the treatment of re-emerging and emerging diseases.

Channels: Immunology, Ebola,

Released:
9-Dec-2019 1:00 AM EST
Feature
Newswise: Texas Biomed continues testing Ebola therapies and vaccines showing promise in outbreak areas

Texas Biomed continues testing Ebola therapies and vaccines showing promise in outbreak areas

Texas Biomedical Research Institute

In mid-August 2019, human clinical trials were halted in the current Ebola epidemic that has claimed more than 2,100 lives in Africa. The findings resulted in the discontinuation of two of the drugs in the trial. Future patients will be randomly assigned to receive either REGN-EB3 (Regeneron) or mAb114 (Ridgeback Biotherapeutics) in an extension phase of the study. Texas Biomedical Research Institute scientists in the Institute’s Biosafety Level 4 contract research program conducted preclinical testing of several of the compounds in the trial, working with Regeneron and the Biomedical Advanced Research and Development Authority (BARDA).

Channels: Immunology, Infectious Diseases, Public Health, Vaccines, Ebola, Grant Funded News,

Released:
26-Sep-2019 12:05 PM EDT
Marketplace
Newswise: Community-Based Wildlife Carcass Surveillance Is Key for Early Detection of Ebola Virus

Community-Based Wildlife Carcass Surveillance Is Key for Early Detection of Ebola Virus

Wildlife Conservation Society

WCS (Wildlife Conservation Society) and NIH (National Institutes of Health) scientists partnered with the Republic of Congo Ministry of Health to develop a low-cost educational outreach program and surveillance system for wildlife mortality that has continued now for over a decade.

Channels: All Journal News, Infectious Diseases, Public Health, Wildlife, Ebola,

Released:
28-Aug-2019 1:05 PM EDT
Feature
Newswise: Machine Learning Helps Create Detailed, Efficient Models of Water

Machine Learning Helps Create Detailed, Efficient Models of Water

Department of Energy, Office of Science

A team devised a way to better model water’s properties. They developed a machine-learning workflow that offers accurate and computationally efficient models.

Channels: Artificial Intelligence, DOE Science News, Energy, Supercomputing, Technology, Ebola, DOE Science News,

Released:
9-Aug-2019 3:05 PM EDT
Expert Pitch
chb-logo.gif

Existing anti-parasitic drug could offer treatment for Ebola

Boston Children's Hospital

Amid the worsening Ebola outbreak in the Congo, now threatening to spill into Rwanda, a new study suggests that an existing, FDA-approved drug called nitazoxanide could potentially help contain this deadly

Channels: All Journal News, Children's Health, Infectious Diseases, Public Health, Ebola,

Released:
8-Aug-2019 3:05 PM EDT
Feature
IDSA HIVMA Joint Logo.png

Declaration of PHEIC in DRC Should Spur Support, Not Fear

Infectious Diseases Society of America (IDSA) and the HIV Medicine Association (HIVMA)

The World Health Organization’s declaration today that the year-long Ebola crisis is a Public Health Emergency of International Concern is hoped to raise much-needed awareness and resources for preparedness and control efforts across the region. The decision was made following new incidents highlighting risks of repeated cross-border spread of the ongoing Ebola outbreak in the Democratic Republic of Congo.

Channels: AIDS and HIV, Infectious Diseases, Public Health, Ebola, U.S. Politics,

Released:
18-Jul-2019 1:05 PM EDT
Research Results

Law and Public Policy



2.41312